ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2024
Pharmacist-Driven Deprescribing to Reduce Anticholinergic Burden in Veterans With Dementia.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Concurrent Use of Anticholinergic and Antidementia Medicines in Older Adults with Dementia: A Systematic Review of Prevalence, Predictors and Clinical Outcomes.Medical sciences (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The American Geriatrics Society Beers Criteria strongly recommends avoiding anticholinergic medications in patients with dementia or cognitive impairment due to the risk of adverse central nervous system effects. In the veteran population, about 35% of patients with dementia are prescribed a medication regimen with a high anticholinergic burden. This article examines the role of pharmacists for reducing anticholinergic burden in veterans with dementia. Observations: Outpatients with dementia or cognitive impairment at the Veterans Affairs Louisville Healthcare System who were prescribed a potentially inappropriate anticholinergic medication as classified by the Beers Criteria were selected using the VIONE (Vital, Important, Optional, Not needed, Every medication has an indication) deprescribing dashboard. Electronic health record medication reviews were completed by a pharmacist. The prescriber and patient's primary care practitioner were advised to perform patient-specific risk-benefit assessments, deprescribe potentially inappropriate anticholinergic medications, and consider safer alternative medications based on the indication. Conclusions: This quality improvement project suggests that with the use of population health management tools and in collaboration with the interdisciplinary team, pharmacists can identify and deprescribe inappropriate anticholinergic medications. Pharmacists can provide evidence-based recommendations to guide risk-benefit discussion and consider safer nonanticholinergic alternatives (both pharmacologic and nonpharmacologic), aiding in anticholinergic deprescribing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.